129 related articles for article (PubMed ID: 12043699)
1. Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma.
Devine SM; Jahagirdar B; van Besien K
Blood; 2002 Jun; 99(11):4251-2; author reply 4252. PubMed ID: 12043699
[No Abstract] [Full Text] [Related]
2. Three courses of high dose therapy. Feasibility in the treatment of multiple myeloma--a "France autogreffe" study.
Colombat P; Milpied N; Laporte JP; Casassus P; Linassier C; Harousseu JL
Cancer; 1994 Dec; 74(11):2930-4. PubMed ID: 7954256
[TBL] [Abstract][Full Text] [Related]
3. Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
Saini NY; Patel R; Varma A; Bashir Q; Delgado R; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
Am J Hematol; 2019 Jan; 94(1):E2-E5. PubMed ID: 30300461
[No Abstract] [Full Text] [Related]
4. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
5. Autologous and allogeneic stem cell transplantation in multiple myeloma.
Goldschmidt H; Egerer G; Ho AD
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S25-6. PubMed ID: 10933182
[TBL] [Abstract][Full Text] [Related]
6. Autologous hematopoietic stem-cell transplantation for multiple myeloma.
Harousseau JL; Moreau P
N Engl J Med; 2009 Jun; 360(25):2645-54. PubMed ID: 19535803
[No Abstract] [Full Text] [Related]
7. [Value of hematopoietic stem cell autotransplantation in the treatment of multiple myeloma: initial experience at the National Bone Marrow Transplantation Center and review of the literature].
Abdelkefi A; Ladeb S; Ben Othman T; Torjman L; Jeddi R; Ben Abdeladhim A
Tunis Med; 2000 Oct; 78(10):548-56. PubMed ID: 11190737
[TBL] [Abstract][Full Text] [Related]
8. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma.
Goldschmidt H; Hegenbart U; Wallmeier M; Hohaus S; Engenhart R; Wannenmacher M; Haas R
Ann Oncol; 1997 Mar; 8(3):243-6. PubMed ID: 9137792
[TBL] [Abstract][Full Text] [Related]
9. Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.
Landau H; Wood K; Chung DJ; Koehne G; Lendvai N; Hassoun H; Lesokhin A; Hoover E; Zheng J; Devlin SM; Giralt S
Leuk Lymphoma; 2016 Aug; 57(8):1781-5. PubMed ID: 26758672
[TBL] [Abstract][Full Text] [Related]
10. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.
Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta JJ; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín JL; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal MJ; Solano C; Leon A; Sánchez JJ; Martínez-Chamorro C; Fernández-Rañada JM
Bone Marrow Transplant; 1998 Jan; 21(2):133-40. PubMed ID: 9489629
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy in multiple myeloma.
Goldschmidt H; Hegenbart U; Wallmeier M; Moos M; Haas R
Leukemia; 1997 Dec; 11 Suppl 5():S27-31. PubMed ID: 9436935
[TBL] [Abstract][Full Text] [Related]
12. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
Hunter HM; Peggs K; Powles R; Rahemtulla A; Mahendra P; Cavenagh J; Littlewood T; Potter M; Hunter A; Pagliuca A; Williams CD; Cook G; Towlson K; Marks David I; Russell NH;
Br J Haematol; 2005 Feb; 128(4):496-502. PubMed ID: 15686458
[TBL] [Abstract][Full Text] [Related]
13. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
14. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
Awedan AA
Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m
Patel P; Oh AL; Koshy M; Sweiss K; Saraf SL; Quigley JG; Khan I; Mahmud N; Hacker E; Ozer H; Peace DJ; Weichselbaum RR; Aydogan B; Rondelli D
Leuk Lymphoma; 2018 Jul; 59(7):1666-1671. PubMed ID: 29065747
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity.
Moreau P; Kergueris MF; Milpied N; Le Tortorec S; Mahé B; Bulabois CE; Rapp MJ; Larousse C; Bataille R; Harousseau JL
Br J Haematol; 1996 Dec; 95(3):527-30. PubMed ID: 8943896
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma.
Barlogie B; Jagannath S; Vesole D; Tricot G
J Hematother; 1994; 3(2):149-53. PubMed ID: 7922016
[TBL] [Abstract][Full Text] [Related]
18. A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
Carella AM; Beltrami G; Corsetti MT; Scalzulli P; Carella AM; Musto P
Haematologica; 2004 Dec; 89(12):1534-6. PubMed ID: 15590410
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of patients with multiple myeloma treated with total body irradiation-Melphalan conditioning.
Munker R; Baghian A; Koleva Y; Andrews P; Matharoo GS; Wright AE; Saba NS; Weiner RS; Safah H
Eur J Haematol; 2017 Jul; 99(1):56-59. PubMed ID: 28370630
[TBL] [Abstract][Full Text] [Related]
20. Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma.
Blanes M; Lorenzo JI; Ribas P; Jiménez A; González JD; Cejalvo MJ; Solano C; Alegre A; de la Rubia J
Ann Hematol; 2019 Aug; 98(8):2013-2015. PubMed ID: 30879095
[No Abstract] [Full Text] [Related]
[Next] [New Search]
